Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Ruikang Pharmaceutical, indicating a slight decline in stock price and specific financing activities [1][2] - As of September 9, Ruikang Pharmaceutical's stock price decreased by 0.68%, with a trading volume of 48.56 million yuan and a net financing purchase of 2.94 million yuan [1] - The company's financing balance is reported at 202 million yuan, which constitutes 4.59% of its market capitalization, indicating a low financing level compared to the past year [1] Group 2 - For the first half of 2025, Ruikang Pharmaceutical reported a revenue of 3.544 billion yuan, reflecting a year-on-year decrease of 12.11%, while the net profit attributable to shareholders was 18.17 million yuan, down 41.45% year-on-year [2] - The company has distributed a total of 393 million yuan in dividends since its A-share listing, with 36.03 million yuan distributed over the past three years [3]

Core Viewpoint - The major shareholder of Ruikang Pharmaceutical has completed a share reduction plan, which does not affect the company's control or governance structure [1]. Summary by Sections Shareholder Actions - The shareholder, Jiangzhou Zhaoshang Huize Pharmaceutical Investment Partnership, reduced its holdings by 100 shares at an average price of 3.00 yuan, representing a decrease of 0.0001% [1]. - After the reduction, the total shares held by Jiangzhou Zhaoshang Huize decreased from 75,235,525 shares to 75,235,425 shares, with the holding percentage dropping from 5.00% to 4.9999% [1]. Compliance and Impact - The company stated that the share reduction complies with relevant laws and regulations and was executed according to a previously disclosed plan, indicating no violations [1]. - Jiangzhou Zhaoshang Huize is not the controlling shareholder or actual controller of the company, and the reduction will not lead to any change in control or impact the company's governance structure and ongoing operations [1].

瑞康医药集团股份有限公司 关于持股5%以上股东股份减持计划实施完成的公告 瑞康医药集团股份有限公司（以下简称"公司"）于 2025 年 5 月 8 日披露 了《关于持股 5%以上股东减持股份的预披露公告》（公告编号：2025-030）， 股东荆州招商慧泽医药投资合伙企业（有限合伙）（以下简称"招商慧泽"）计 划在该公告披露之日起 15 个交易日后的 3 个月内以集中竞价或大宗交易的方式 减持公司股份不超过 15,047,105 股（占公司总股本比例 1%）。 近日，公司收到招商慧泽出具的《关于股份减持计划期限届满的告知函》， 获悉上述股东的股份减持计划已实施完毕，现将相关情况公告如下： 一、股东减持情况 1、股东减持股份情况 | 股东名称 | 减持方式 | 减持期间 | | 减持均价 | 减持数量 | 减持比例 | | --- | --- | --- | --- | --- | --- | --- | | 招商慧泽 | 集中竞价交 | 2025 年 | 5 月 | 3.00 | 100 | 0.0001 | | | 易 | 日 30 | | | | | 证券代码：002589 证券简称：瑞康医药 公告编号：2 ...

Core Viewpoint - Ruikang Pharmaceutical (002589) announced that as of the date of the announcement, the company has no overdue guarantees, no guarantee amounts involved in litigation, and no losses incurred due to being judged against in guarantee cases [1] Group 1 - The company has confirmed the absence of overdue guarantees [1] - There are no guarantee amounts related to any ongoing litigation [1] - The company has not incurred any losses from guarantees due to adverse judgments [1]

Core Points - The company held its 18th meeting of the 5th Board of Directors on September 5, 2025, with all 8 directors present, and the meeting was conducted in accordance with relevant laws and regulations [1] - The Board approved the revision of the company's articles of association to align with the latest legal requirements and the company's development strategy, with a unanimous vote of 8 in favor [1] - The Board also approved the revision of certain governance systems to enhance the company's governance structure, again with a unanimous vote of 8 in favor [2] - The company proposed a guarantee limit for itself and its subsidiaries totaling no more than RMB 2 billion, with specific limits based on the subsidiaries' asset-liability ratios, which was also approved unanimously [3] - A proposal to convene the 2025 first extraordinary general meeting was approved with a unanimous vote of 8 in favor [3]

Meeting Details - The company will hold its first extraordinary general meeting of shareholders in 2025 on September 22, 2025, at 15:00 [1] - Shareholders can participate through on-site voting or online voting, with specific time slots for online voting provided [2][5] - The deadline for registration for the meeting is September 18, 2025, at 15:00 [4] Voting Procedures - Shareholders can only choose one method of voting: on-site or online, and any duplicate votes will be disregarded [2] - The meeting will require a two-thirds majority of the voting rights held by attending shareholders for special resolutions [3] Registration Requirements - Legal representatives of corporate shareholders must provide specific documentation for registration, while individual shareholders must present their identification and shareholder account cards [3][4] - Remote shareholders can register via mail or email, but phone registrations are not accepted [4] Contact Information - The company has provided contact details for inquiries, including a phone number and email address for shareholder communication [5][6]

Summary of Key Points Core Viewpoint The company, Ruikang Pharmaceutical Group Co., Ltd., has revised its Articles of Association and certain governance systems, which will be submitted for shareholder approval. The revisions are in accordance with relevant laws and regulations, reflecting the company's actual situation. Group 1: Revision of Articles of Association - The company has made amendments to its Articles of Association based on the Company Law of the People's Republic of China and other relevant regulations [1][2][3] - The revised Articles of Association will be submitted for approval at the upcoming shareholders' meeting [1][2] - The updated Articles of Association have been published on the official website for public access [1] Group 2: Governance Structure Changes - The legal representative of the company will be the director responsible for executing company affairs, and the resignation of the legal representative will require the appointment of a new representative within thirty days [2][3] - The company will bear civil liability for the legal activities conducted by its legal representative, and may seek compensation from the representative if there is fault [2][3] - The company’s governance structure aims to ensure compliance and operational efficiency, enhancing shareholder value and corporate responsibility [4][5]

Summary of Key Points Core Viewpoint - 瑞康医药集团股份有限公司 has approved a proposal to provide guarantees for its subsidiaries, with a total guarantee limit not exceeding RMB 2 billion, aimed at ensuring smooth operational financing and enhancing management of external guarantees [1][2]. Group 1: Guarantee Overview - The company plans to provide guarantees for its subsidiaries, with a total limit of RMB 2 billion, including a maximum of RMB 1 billion for subsidiaries with a debt-to-asset ratio above 70% [1]. - The guarantees will cover various financing activities such as comprehensive credit applications, loans, and leasing [2]. - The actual guarantee amounts will be determined based on specific agreements and will not require additional board or shareholder meetings for approval within the set limits [2]. Group 2: Financial Risk Management - All guaranteed entities are within the company's consolidated financial statements, and the financial risks are considered manageable [2][3]. - As of the announcement date, the company has provided guarantees totaling RMB 545.20 million, representing 9.85% of the audited net assets attributable to the parent company for 2024 [3]. - The company has no overdue guarantees or any litigation related to guarantees as of the announcement date [3]. Group 3: Board of Directors' Opinion - The board believes that providing guarantees for wholly-owned and controlled subsidiaries is necessary for the company's operations and business development [3]. - The risks associated with these guarantees are deemed controllable, and there is no harm to the interests of the company or its shareholders, particularly minority shareholders [3].

Core Points - The company, Realcan Pharmaceutical Group Co., Ltd., was established in December 2009 and is registered in Yantai, Shandong Province with a registered capital of RMB 1,504.71 million [2][3][7] - The company aims to enhance health services through innovation and compliance, focusing on a digital, integrated, and intelligent pharmaceutical supply chain [8][9] - The company has undergone several rounds of public and private share issuance, with the latest being a non-public offering in 2016 [3][10] Company Structure - The company operates as a joint-stock limited company, with its legal representative being the chairman of the board [4] - The company has a total of 150,471.0471 million shares issued, all of which are ordinary shares [11][12] - The company is governed by its articles of association, which outline the rights and responsibilities of shareholders, directors, and senior management [4][16] Business Operations - The company's business scope includes the sale of various medical and pharmaceutical products, including medical devices, health foods, and agricultural products [9] - The company is committed to fulfilling its social responsibilities as a key player in the national pharmaceutical supply chain [8] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends, participate in shareholder meetings, and access company documents [16][17] - Shareholders are required to report any changes in their shareholding that exceed 3% [22][23] - The company has provisions to protect shareholder interests and ensure compliance with legal obligations [19][20]

General Principles - The rules are established to regulate the behavior of Ruikang Pharmaceutical Group Co., Ltd. and ensure that the shareholders' meeting exercises its powers in accordance with relevant laws and regulations [3][4] - The company must strictly follow legal and regulatory requirements when convening shareholders' meetings to ensure shareholders can exercise their rights [3][4] Shareholders' Meeting Convening - The shareholders' meeting is categorized into annual and extraordinary meetings, with annual meetings held within six months after the end of the previous fiscal year [3][5] - Extraordinary meetings must be convened within two months under specific circumstances, such as insufficient board members or significant losses [3][5][6] - If the company cannot convene a meeting within the specified time, it must report to the relevant regulatory authorities and disclose the reasons [4] Proposals and Notifications - Proposals must fall within the scope of the shareholders' meeting's authority and comply with legal and regulatory requirements [9][14] - The company must notify shareholders of the meeting at least 20 days in advance for annual meetings and 15 days for extraordinary meetings [16][17] - Notifications must include details such as meeting time, location, agenda, and the rights of shareholders to attend and vote [17][18] Meeting Procedures - The shareholders' meeting should be held at the company's registered address or another location specified in the articles of association, and it can also utilize electronic communication methods [21][22] - Shareholders can attend in person or appoint proxies to vote on their behalf, with each share carrying one vote [24][25] - The meeting must be recorded, and the minutes should include details such as attendees, proposals discussed, and voting results [35][36] Voting and Resolutions - Resolutions can be ordinary or special, with ordinary resolutions requiring a simple majority and special resolutions requiring two-thirds approval from attending shareholders [38][39] - Certain matters, such as capital changes or amendments to the articles of association, require special resolutions [40][41] - Voting results must be disclosed promptly, including details of the number of votes and the outcome of each proposal [53][54] Legal Compliance - The company must ensure that the resolutions passed at the shareholders' meeting comply with laws and regulations, and shareholders can challenge invalid resolutions within a specified timeframe [58][26] - The company is responsible for disclosing information related to any legal judgments or regulatory requirements that may affect its operations [26]